ClinicalTrials.govpublic full text
A Study Evaluating Ficerafusp Alfa (BCA101) QW in Combination With Pembrolizumab vs Alternative Ficerafusp Alfa Dosing in 1L R or M HNSCC
metastatic head and neck squamous cell carcinoma, recurrent head and neck squamous cell carcinoma, head and neck cancer, hnscc, recurrent hnscc, metastatic hnscc, first line treatment, phase 2, pembrolizumab, pd-l1+, tgf-beta, oral cavity
This document is indexed with metadata only — full text is not available in the archive for this record.
Open the official source ↗
Record · ID 889697
Retrieved via
Conceptio — every document is proof-bundled with source, license, and retrieval metadata.